Page 8 - Martin Shkreli Case Study

DARAPRIM

Shkreli often portrayed as an
entrepreneur, hedge fund

investor bought Turing
Pharmaceuticals and then acquired and raised the cost of Daraprim, a
life-saving drug for people with HIV and weakened immune systems
from £13.50 per pill to £750 a 5,556% rise.

Daraprim costs about $1 to produce and fights toxoplasmosis, the
second most common food borne disease, which can easily infect
people whose immune systems have been weakened by HIV,
chemotherapy, malaria or pregnancy.

- 2010 GlaxoSmithKline sold marketing rights of Daraprim to
CorePharma. Daraprim sold for $1 per pill.

- 2014 Impax Laboratories bought Core and affiliated companies
for $700m

- 2015 (Aug) Impax sold Daraprim to Turing Pharmaceuticals for
$55m. On the same day Turing announced it had raised $90m
from Mr. Shkreli and other investors.

Daraprim is known generically as pyrimethamine and was first approved
by the Federal Drug Administration in 1953